GlassScriptPrepare for your visit
Dylan Caggiano
Addiction Medicine (Family Medicine) · Mobile, AL · NPI 1851873079
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$291.86
in general payments reported to CMS, 2019-2025 · $20.35 in 2025
The $20.35 reported for 2025 was less than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
Who reported paying
General payments only, top 6 by amount.
- Indivior INC. $87.82
- Otsuka America Pharmaceutical, INC. $81.37
- Abbvie INC. $42.18
- Alkermes, INC. $26.58
- Astrazeneca Pharmaceuticals LP $20.35
- Janssen Pharmaceuticals, INC $16.88
Drugs and devices associated with these payments
Aristada Perseris Abilify Maintena Vraylar Lybalvi Airsupra Spravato Cologuard Collection Kit
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Dylan Caggiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/11420091/dylan-caggiano